 Skye Bioscience Inc OTCQB:SKYE said the US Food and Drug Administration FDA has authorized it to proceed with the Investigational New Drug IND application for SBI-100 Ophthalmic Emulsion OE, a synthetic cannabinoid derivative that targets the CB1 receptor, which plays a key role in managing intraocular pressure. The company can now initiate clinical trials in the US, including its planned Phase 2 study for primary open-angle glaucoma or ocular hypertension in the first half of 2023. 